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Dear Editor,
Enclosed is our manuscript, entitled “Relationship of faecal calprotectin and long-term outcomes in 
Finnish patients with Crohn’s Disease: Retrospective multi-centre chart review study” for 
consideration for publication in Scandinavian Journal of Gastroenterology. Apart from the 
conference presentation in ECCO Congress 2018 in Vienna, the work has not been previously 
published or simultaneously submitted for publication in any format. A previous version of the 
manuscript was submitted to Scandinavian Journal of Gastroenterlogy. Based on the referee 
comments received, the manuscript has been rewritten.
 
The manuscript assesses the association of faecal calprotectin (FC) 1 year (±2 months) after 
biological therapy initiation with composite event-free survival (CEFS) consisting of surgical 
procedures, corticosteroid initiation, treatment failure or dose increase in patients with Crohn’s 
disease (CD), and dependencies between faecal calprotectin and other tests of disease activity. 
The reported study is a retrospective registry study that was performed in 4 Finnish clinics and 
includes all adult patients who initiated biological therapy in the clinics. Our study showed that an 
increase in faecal calprotectin was associated with an increased risk of surgery and composite 
outcomes of Crohn’s Disease.  
All authors have made substantial contributions to all of the following: (1) the conception and 
design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the 
article or revising it critically for important intellectual content, (3) final approval of the version to be 
submitted. The study was funded by Janssen-Cilag, Espoo, Finland. Employees of Janssen-Cilag 
are study authors and as such they contributed to the study design, design and interpretation of 
data analyses, and to the writing the manuscript.
Sincerely Yours,
Pauliina Molander
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Relationship of faecal calprotectin and long-term outcomes in Finnish patients with 
Crohn’s Disease: retrospective multi-centre chart review study
Background and Aims: A retrospective non-interventional, multi-centre patient chart 
review study was conducted to investigate the association of faecal calprotectin (FC) 1 
year (±2 months) after biological therapy initiation with composite event-free survival 
(CEFS) consisting of surgical procedures, corticosteroid initiation, treatment failure or 
dose increase in patients with Crohn’s disease (CD). In addition, the correlations of FC 
and other tests of disease activity were assessed. 
Materials and methods: Data on Finnish CD patients initiating a biological therapy 
between 2010 and 2016, were collected. The association of FC and CEFS was analysed 
with Kaplan-Meier and Cox proportional hazard modelling. The correlations were 
tested with Pearson’s test.  
Results: Biological therapy was initiated in 186 patients, of which 87 (46.8%) had FC 
results available at one year and 80 had follow-up exceeding 14 months. The 
characteristics of patients with and without FC results were similar. Patients with 
elevated FC (>250 µg/g) had a significantly increased risk of experiencing composite 
event (HR 3.4, 95% CI: 1.3-8.9; p=0.013) when compared to patients with normal FC 
(FC≤100). No such risk was observed in patients with intermediately increased FC 
level (100 µg/g<FC≤250 µg/g) (HR 2.2 (95% CI: 0.8-6.2; p=0.120). FC value had 
significant positive correlation with CRP, HBI and leukocyte values when measured at 
similar timepoints. 
Conclusions: Elevated level of FC approximately one year after the initiation of 
biological therapy was associated with an increased risk of either surgical procedures, 
corticosteroid initiation, treatment failure or dose increase (i.e. composite outcome) in 
patients with CD.
Keywords: Biological treatment, Crohn’s disease, faecal calprotectin, outcomes
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Background
Calprotectin is a calcium-binding protein that is one of the major cytosolic proteins in 
neutrophils. As calprotectin is stable in feces, it can be used as a marker for neutrophil 
infiltration into gastrointestinal tissues and therefore of gut inflammation.1 In inflammatory 
bowel disease (IBD), elevated faecal calprotectin (FC) levels are observed during the 
intestinal inflammation due to migration of neutrophils through the inflamed bowel wall of 
the gastrointestinal tract.2,3 FC seems to be a more sensitive marker of active disease 
compared with other frequently used surrogate markers such as C-reactive protein (CRP) in 
both Crohn’s disease (CD) and ulcerative colitis.4,5 As IBD flares are often unpredictable 
resulting in unfavourable clinical course of the disease, a reliable prognostic biomarkers are 
needed to facilitate treatment decisions.  
A recent systematic literature review suggests that in patients with IBD, consecutive 
FC levels within the normal range predict maintenance of remission while abnormal FC 
levels predict disease relapse in the following 2-3 months.6-9 Some controversies still remain 
in determine the most reliable cut-off level for endoscopically inactive disease. In CD 
patients, FC levels greater than 100 μg/g have indicated endoscopic recurrence and levels 
below 51 μg/g maintenance of remission after surgery.10 Cut-off points of 54 μg/g for low 
and 122 μg/g for high endoscopic disease activity have also been suggested.11 In addition, a 
prior analysis12 revealed a significantly larger number of hospitalizations or surgery in CD 
patients with FC at least 200 ug/g compared with FC less than 200 ug/g. In fact, it has been 
suggested that a lower threshold for endoscopic evaluation may be needed in CD patients 
with post-surgery surveillance as endoscopic recurrence is associated with considerably lower 
FC values than in surgery-naïve CD patients.13 Notably, a study by D’Haens and coworkers 
reported that FC levels below 250 μg/g had 94% sensitivity and 62% specificity in predicting 
mucosal healing in CD patients.14 These findings have gained ground in recent years.15
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However, little is known on the association of FC and long-term outcomes such as the 
need for surgeries. 
The current study, a REtrospective non-interventional Chart review study of the 
RElationship of Fecal calprotectin and long-term Outcomes in adult patients with CD 
(RECREFO), was conducted in clinical practice setting to assess the potential association of 
FC 1 year (±2 months) after biological therapy initiation and long-term outcomes measured 
here as composite event-free survival (CEFS). The CEFS included surgical procedures, 
corticosteroid initiation, biological treatment failure, and biological dose increase. 
Furthermore, the correlations b tween FC test results and other indicators of clinical activity, 
such as CRP, were assessed as secondary outcomes. In addition, as the lack of FC test results 
at the timepoint of interest was more common than expected, an additional analysis for 
representativeness was made to assess whether there were systematic differences in the 
characteristics, drug use or outcomes of the patients with and without FC testing at one year 
(±2 months) after biological therapy initiation.
Methods
The RECREFO study was based on individual patient-level real-world data that were 
gathered locally from the patient charts between December 2016 and July 2017 by senior 
gastroenterologists at four major IBD clinics (Helsinki University Hospital/Peijas Hospital 
and Jorvi Hospital, Tampere University Hospital, and Turku University Central Hospital) in 
Finland. The catchment area was approximately 1.6 million inhabitants (29% of the Finnish 
population). The study was approved by the ethics committee of Tampere University 
Hospital, and by the local register holders (No: R16121). 
Inclusion criteria
Eligible patients for the RECREFO study were adult patients (age at least 18 years) with 
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confirmed diagnosis of CD (ICD-10 code K50), who had initiated a biological therapy for 
CD at any time between January 1st 2010 and June 30th 2016. 
Faecal calprotectin tests
FC was measured by the quantitative CALPRO® calprotectin enzyme-linked immunosorbent 
assay (ELISA) test (ALP; Calpro AB, Lysaker, Norway) in Peijas and Jorvi Hospitals in 
Helsinki region, and until 2014 in Tampere and until 2016 in Turku.  In Tampere, a 
quantitative fluorescence enzyme immunoassay EliA™ Calprotectin test (Thermo Fisher 
Scientific; Phadia GmbH, Freiburg, Germany) was used after 2014. In Turku, a PhiCal® 
Calprotectin enzyme-linked immunosorbent assay (ELISA K6927) test (Immundiagnostik 
AG, Bensheim, Germany) was used between 2012-2015, and after 2016 the EliA™ 
Calprotectin test was used.  The value considered as normal for FC was less than 100 µg/g16 
in all four hospitals during the study period. 
Data
In line with evidence-based medicine, and a broader health economic and outcomes research 
rationale behind the RECREFO study, the collected data covered information needed for the 
PICOSTEPS (patient, intervention, comparator, outcome, setting, time, effects, perspective, 
sensitivity) framework.17-18 Specifically, the data included patient characteristics (weight, 
height, date of birth, gender, place of birth (country or municipality), smoking status, 
comorbidities, socioeconomic status (education, profession, marital status), used drug 
treatments (drug, dosing regimen, biological therapy intensification, adverse events), long-
term outcomes measured as CD characteristics (location, progression patterns, Crohn’s 
disease activity index [CDAI19], Harvey-Bradshaw index [HBI20], simple endoscopic score 
for Crohn’s disease [SES-CD21], surgical procedures), setting (secondary care clinic), time 
(dates), short-term effects (indicators) measured as laboratory test results (FC, CRP, 
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erythrocyte sedimentation rate [ESR], haemoglobin [Hb], leucocytes, thrombocytes and 
serum albumin, tests associated with biological therapy), and societal perspective including 
health care resource use (surgical procedures, outpatient visits, inpatient stays, imaging, 
endoscopies, infusion visits) and absenteeism. 
The data available in the patient charts were collected systematically by experienced 
gastroenterologists using an electronic clinical research form (eCRF) built in Microsoft Word 
and compiled automatically to a data matrix with visual basic for applications (VBA) to 
minimize human errors. Data not available in the patient charts was considered as missing.
Outcomes
To assess whether patients with and without FC test results at 1 year (±2 months) after 
biological therapy initiation had different characteristics (at the start of therapy), the study 
population was classified to groups with and without FC test results. The patients with FC 
measurement formed the FC group whereas the remaining patients formed the non-FC group. 
To allow for unbiased between-group comparisons, patients with less than 14 months of 
follow-up after biological therapy initiation were excluded.  
For the analysis of the association of FC test results and CEFS, composite event was 
defined as a performed surgical procedure, corticosteroid initiation (or re-initiation for 
patients using corticosteroids at baseline), biological therapy failure, or dose increase, 
whichever occurred first after the FC assessment at approximately 1 year. Biological therapy 
failure was defined as drug discontinuation related to inefficacy or adverse events. Biological 
therapy dose increase was defined as an increase of the administered dose or a shortening of 
the administration interval. Preceeding the 1-year measurements, the patients could have had 
dose increases, adverse event, therapy failure or switch of therapy or both, corticosteroid 
initiation, and surgery. Thus, the CEFS analysis assesses, whether these events occurred 
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recurrently or for the first time after the 1-year FC measurement. The CEFS analysis was 
performed for patients in the FC group (i.e. patients with follow-up exceeding 14 months).
The associations between FC and the other indicators of disease activity (CRP, Hb, 
leucocytes, HBI, SES-CD, and ESR) were assessed as secondary outcomes based on data 
from the full study population (n=186).
Statistics
Summary measures for the variables were reported as mean and standard deviation (SD), 
proportions (%) and median. Proportion tests (pr-test, categorical variables) and t-tests (t-test 
for equality of means, continuous variables) were used to describe whether the patient 
characteristics and outcomes were similar in the FC and non-FC groups.  
The associations of FC at one year (initiation of time for analysis) with successive 
CEFS was analysed using Kaplan-Meier methods, and Cox proportional hazard univariate 
and multivariate models. For the analysis, the patient’s FC level at one year was classified as 
normal (FC≤100 µg/g), intermediate (100 µg/g<FC≤250 µg/g) or elevated (FC>250 µg/g). In 
sensitivity analysis, the impact of additional covariates (age, gender, disease location, disease 
behaviour, perianal disease) on the outcome were assessed. The proportional hazards 
assumption was tested with Schoenfeld residuals.
Pearson’s correlation coefficients (r) for FC and other indicators of disease activity 
were estimated, and the significance of the correlation was tested with Pearson’s tests for 
significance. A P-value below 0.050 was considered to indicate statistical significance. All 
analyses were performed with Stata/MP 14.2 for Windows.22
Results
Patients
RECREFO study population included 186 patients. FC test had been performed at 
approximately one year after biological therapy initiation in 87 (46.8%) patients and was 
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missing in 99 patients (53.2%). Follow-up duration exceeded 14 months in 80 (92.0%) and 
70 patients (70.7%) with (FC group) and without (non-FC) FC test, respectively. 
The characteristics of FC and non-FC groups were similar at baseline (Table 1) [Table 
1 near here]. The patients were on average 44 years old and had CD duration of 
approximately ten years at the start of follow-up. Prior treatment with biologics and systemic 
non-biologic medications was similar in FC and non-FC groups at baseline. Similarly, no 
significant differences were observed in the duration of follow-up (1183.36 vs 1325.14 days, 
respectively, p=0.165). A larger proportion of patients were male in the non-FC group 
(65.7% vs 51.3%) and the mean CRP was higher at baseline in FC group, though the 
differences were not statistically significant. The only statistically significant difference 
between FC and non-FC groups at baseline was observed in the leukocyte values (8.47 vs 
6.89 109/L, respectively, p=0.003). 
Faecal calprotectin and composite event-free survival
At at one year after biological therapy initiation, 34 patients (42.5%), 18 patients (22.5%) and 
28 patients (35.0%) had normal, intermediate and elevated FC level, respectively. The CEFS 
analysis included the patients in FC group (80 patients) who had altogether 26 composite 
events consisting of dose increases (54.3%), inefficacy (11.4%), adverse events (5.7%) and 
surgery (2.9%). The follow-up duration from the FC measurement at at one year until the end 
of data collection was on average 2.3 years (SD 1.7, median 1.8 years). The Kaplan-Meier 
curves for the CEFS according to the observed FC level are depicted in Figure 1. [Figure 1 
near here] The log-rank test for equality of survivor functions showed a statistically 
significant difference between the FC level groups (p=0.033). 
The total time at risk of the composite event was 124.2 years and the mean per patient 
time at risk was 1.6 years (median 0.8 years, range 0.02-5.2). When FC class at one year was 
included in the Cox model as the only covariate, patients with elevated FC had a significantly 
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increased risk of experiencing a composite event (HR 3.4, 95% CI: 1.3-8.9; p=0.013) when 
compared to patients with normal FC. No such significantly increased risk was observed in 
patients with intermediate FC levels (HR for composite event 2.2 (95% CI: 0.8-6.2; p=0.120). 
Inclusion of age, gender, and disease characteristics (location, behaviour, perianal disease) as 
covariates in the Cox model analysis led to a statistically significant increase in the risk of 
experiencing a composite event in patients who had intermediate FC (HR: 3.3, 95% CI 1.1-
10.4; p=0.036) and a further elevated risk in patients with elevated FC (HR: 4.8, 95% CI: 1.6-
14.3; p=0.005) when compared to patients with normal FC. However, none of the additional 
covariates had statistically significant associations with the risk of a composite event in the 
multivariate analysis.
Faecal calprotectin and other indicators of clinical activity
FC at the time of biological therapy initiation had statistically significant positive correlations 
with CRP (r=0.33), leucocytes (r=0.23) and HBI (r=0.28; Figure 2) [Figure 2 near here]. 
When measured at approximately one year, FC still had statistically significant positive 
correlations with CRP (r=0.36), leucocytes (r=0.27), and HBI (r=0.43), but now significant 
negative correlations were also observed with FC and Hb (r=-0.26). 
CRP, leucocytes and HBI had strong, statistically significant and robust associations 
with FC when measured at similar timepoints. In addition, changes in FC during the first year 
after biological therapy initiation had a significant correlation with changes in HBI (r=0.39) 
and CRP (r=0.40).
Discussion
The maintenance of long-term remission is of critical importance in IBD, as failure to control 
disease activity is associated not only with impaired quality of life but also worse long-term 
outcomes. The current RECREFO study, carried out in four major IBD centers covering 
approximately 1.6 million Finnish inhabitants, demonstrated a robust association between FC 
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and both short-term disease activity indicators and long-term clinical outcomes in patients 
with CD. A statistically significant increase in the risk of successive composite event was 
observed, when FC values were elevated (>250 ug/g) at one year after biological therapy 
initiation. In addition, FC was found to be a robust and statistically significant predictor of 
the CEFS in the sensitivity analyses while other potential predictors (e.g. age, gender, disease 
characteristics) were not. 
Earlier studies have demonstrated that clinical symptoms correlate poorly with 
intestinal inflammatory activity or mucosal healing.23-25 Therefore, clinical remission should 
be paired with biological and endoscopic evidence of mucosal inflammatory inactivity while 
assessing the treatment outcom . Biological inactivity may be indicated by the absence of 
markers of inflammation such as ESR, CRP and FC.  However, ESR would take several days 
to respond to the changes in inflammation status and therefore ESR appeared to be a less 
accurate measure of disease activity in IBD compared with CRP.26 In the present study, FC 
values had significant and consistent positive associations with CRP, HBI and leukocyte 
levels when measured at similar time points. Significant correlations were also observed 
between changes in FC over time and changes in CRP and HBI.  These findings alone 
demonstrate that FC has a strong correlation with clinical activity index and conventional 
inflammatory markers.  Moreover, a correlation between inflammatory activity and FC has 
been established27, and thus FC monitoring has the potential to detect higher rate of 
asymptomatic patients with IBD with ongoing inflammation of mucosa, especially among 
IBD patients who under report disease symptoms. Importantly, mucosal healing has been 
associated with a lower risk of hospitalisation and surgery, improved symptom control and 
reduced corticosteroid use, overall better long-term outcomes and a reduced risk of clinical 
and surgical relapse following ileocolic resection in patients with CD.28-33 Repeated 
endoscopic or radiological assessment is not always feasible for the patient especially 
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considering bowel preparation for the colonoscopy and possible absenteeism. In fact, the use 
of FC as an activity biomarker in IBD holds the additional benefit of being specific for 
intestinal inflammation and not affected by systemic or extra intestinal inflammation, as is the 
case with CRP or ESR. These aspects alone suggest that FC monitoring has the potential to 
serve as a reliable prognostic biomarker while facilitating treatment decisions. 
It has been suggested that the CD phenotype could influence the predictive value of 
FC. Previous reports showed that FC can predict relapse, particularly in patients with colonic 
and ileocolonic CD, but not in those with ileal disease.34,35 In our study, the differences in the 
CEFS analysis was not found to depend on the localisation of the disease and, thus, patients 
with ileal disease were included in the analysis. 
This study provided important evidence that FC is an important and clinically 
meaningful predictor for CEFS among patients with CD. In prior studies, FC cut-off levels 
have shown to associate the clinical value of FC measurement with endoscopic recurrence 
and maintenance of remission after surgery10, as well as with low and high disease activity in 
patients with CD.11 A meta-analysis of 13 studies compared the cut-off FC levels of 50 µg/g, 
100 µg/g and 250 µg/g, and found that with the higher cut-off levels the sensitivity decreased, 
while the specificity increased.36 Even to date some controversy remains in regards to 
defining the optimal cut-off value. 
However, a distinction needs to be made based on the primary objective for 
establishing FC cut-off level, i.e. is the cut-off primarily aimed at defining remission or active 
CD. In clinical practice, it is usually most difficult to determine whether CD is active or 
inactive among patients with FC in the “grey area”, i.e. the range of the intermediate FC of 
100-250 µg/g. Even though this study is based on a small patient number, the results support 
the conclusion that intermediate FC at approximately one year after treatment initiation is 
likely to indicate a more active than an inactive CD, at least in terms of the risk of 
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experiencing any of the composite events. Therefore, we suggest that the CD patients with 
intermediate FC should undergo an intensive clinical examination to verify the activity of the 
disease, and if needed, have their treatment intensified accordingly.
This study has inherent limitations. The study was based on data available from 
patient charts, therefore the quality of the analysis depends on the accuracy and completeness 
of the patient records. When the study was designed, a maximum 200 patients was expected 
to be eligible for the analysis. However, only 87 patients had FC values available at 
approximately one year after biological therapy initiation. When FC was handled as a 
continuous variable in a previously performed Cox proportional hazard analysis,  a 
statistically significant increase in the expected hazard of surgery as FC increases was 
observed (HR 1.001176, 95% CI:1.0004-1.0019, p=0.002).37 However, due to the modest 
number of patients and small number of surgical procedures among the study population, no 
definitive conclusions could be drawn based on the analysis and further studies are therefore 
warranted. However, the CEFS results were based on a relatively high proportion of failures, 
where the failed population was large enough to constitute a basis for solid statistical 
analysis. 
In conclusion, the present study shows that an elevated level of FC approximately one 
year after the initiation of biological therapy was associated with an increased risk of either 
surgical procedures, corticosteroid initiation, treatment failure or dose increase (i.e. 
composite outcome) in patients with CD. Despite the limited number of patients in the 
present study, the totality of available data and current findings indicate that FC testing can 
be used as a reliable tool in monitoring CD patients. Further studies are needed to verify the 
current results. 
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Table 1. Patient characteristics at the start of biological therapy initiation. 
Characteristic All patients
(n=186)
FC
(n=80)
Non-FC
(n=70)
FC vs 
Non-FC
n Mean 
(SD)
n Mean 
(SD)
n Mean 
(SD)
p-value
Age, years 185 43.3 
(14.5)
80 44.4 
(15.1)
69 43.9 
(13.4)
0.839
Weight, kg 180 74.8 
(15.1)
77 74.1 
(15.5)
67 76.1 
(15.0)
0.441
Height, cm 144 172.7 
(11.5)
65 173.4 
(8.6)
49 171.7 
(14.9)
0.444
Disease duration, 
years
184 10.1 (9.7) 79 9.4 (9.1) 70 10.7 
(10.3)
0.406
Number of 
previous 
biological 
therapies
186 0.4 (0.7) 80 0.4 (0.6) 70 0.5 (0.7)
Disease activity
   HBI 137 5.8 (5.1) 59 6.4 (5.2) 48 5.1 (4.4) 0.164
    SES-CD 52 13.1 (7.4) 19 12.9 
(6.7)
22 12.5 
(7.0)
0.853
    CRP, mg/l 171 12.2 
(17.1)
73 13.6 
(20.4)
67 9.0 
(11.0)
0.096
   Leukocytes, 
109/l
76 8.5(3.5) 69 6.9 (2.9) 0.003**
   FC, g/g 104 1018 
(1085.8)
56 874.5 
(766.3)
26 799.1 
(977.6)
0.706
  ESR, mm/h 100 33.2 
(24.7)
39 30.2 
(13.5)
50 34.1 
(31.9)
0.477
  Hb, g/l 180 129.8 
(19.7)
79 130.1 
(18.5)
68 130.1 
(22.2)
0.999
n % n % n %
Index therapy 186 80 70
   Adalimumab 66 35.5 30 37.50 29 41.43 0.623
   Infliximab 106 57.0 46 57.50 39 55.71 0.826
   Vedolizumab 14 7.5 <5 <5 0.504
Gender, male 101/186 54.3 41/80 51.3 46/70 65.7 0.073
Smoking 25/130 19.2 13/63 20.6 10/47 21.3 0.935
Prior biologic 
treatment
63/186 33.9 27/80 33.8 25/70 35.7 0.801
Drugs at baseline 186 80 70
   Corticosteroids 47 25.3 23 28.8 14 20.0 0.215
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   Thiopurines 88 47.3 37 46.3 35 50.0 0.647
   Methotrexate 27 14.5 14 17.5 6 8.6 0.109
   MP-6 12 6.5 <5 6 8.6 0.382
Montreal 
classification
186 80 70
  Age at diagnosis
    A1 13 7.0 <5 5 7.1 0.356
    A2 118 63.4 52 65.0 45 64.3 0.927
    A3 55 29.6 25 31.3 20 28.6 0.721
  Location
    L1 35 18.8 16 20.0 13 18.6 0.825
    L2 47 25.3 17 21.3 21 30.0 0.219
    L3 104 55.9 47 58.8 36 51.4 0.368
  Behaviour
    B1 92 49.5 40 50.0 33 47.1 0.727
    B2 73 39.3 34 42.5 26 37.1 0.504
    B3 21 11.3 6 7.5 11 15.7 0.113
  Perianal 50 26.9 21 26.3 21 30.0 0.610
FC, faecal calprotectin; **p<0.010; HBI, Harvey-Bradshaw index; SES-CD, simple 
endoscopic score for Crohn’s disease; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate; Hb, haemoglobin.
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Figure 1. Kaplan Meier survival estimate for the composite event-free survival of CD 
patients. Analysis time starts from the FC measurement occurring approximately 1 year after 
biological therapy initiation. Figure legend: FC, faecal calprotectin; normal, FC≤100 µg/g; 
intermediate, 100 µg/g<FC≤250 µg/g; elevated, FC>250 µg/g.
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Figure 2. Association of faecal calprotectin with other indicators of disease activity in 
patients with CD. Figure legend: FC, faecal calprotectin; **p<0.010; *p<0.050; HBI, 
Harvey-Bradshaw index; SES-CD, simple endoscopic score for Crohn’s disease; CRP, C-
reactive protein; ESR, erythrocyte sedimentation rate; Hb, haemoglobin.
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